mipomersen sodium

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2013
012320082013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
INTRODUCTION Mipomersen is a first-in-class drug indicated as an adjunct to lipid-lowering medications and diet to reduce low… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
Bronchodilator A combination product containing vilanterol trifenatate and fluticasone furoate (Breo Ellipta—GlaxoSmithKline) has… (More)
Is this relevant?
2013
2013
Homozygous familial hypercholesterolemia (HoFH) has the highest cardiovascular risk of any known atherosclerotic disease, with… (More)
Is this relevant?
2012
2012
irreversible proteasome inhibitor for multiple myeloma. Some drugs addressing unmet oncology needs (pancreatic and mesothelioma… (More)
Is this relevant?
Review
2011
Review
2011
In collaboration with Genzyme, Isis Pharmaceuticals has developed mipomersen sodium (ISIS-310312), a synthetic second-generation… (More)
Is this relevant?
Review
2011
Review
2011
Ezetimibe is the first agent used in hypercholesterolemia treatment known to lower intestinal cholesterol uptake that is able to… (More)
Is this relevant?
2009
2009
BACKGROUND AND OBJECTIVES Mipomersen sodium (ISIS 301012) is a 20-mer phosphorothioate antisense oligonucleotide that is… (More)
Is this relevant?
Review
2008
Review
2008
Low-density lipoprotein-cholesterol (LDL-C) lowering is the mainstay of the current treatment guidelines in the management of… (More)
Is this relevant?